In phase I clinical trial, autologous ascites-derived EVs combined with granulocyte-macrophage colony stimulating factor (GM-CSF) is feasible and safe immunotherapy for colorectal cancer treatment (Wolfers et al., 2001). Here, CSF2 is linked to colorectal cancer.